Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,324 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis
Interventions
Web Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 9 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
Interventions
Durvalumab, Guadecitabine
Biological · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Peritoneal Neoplasms
Interventions
nanoparticulate paclitaxel
Drug
Lead sponsor
CritiTech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma
Conditions
Pancreatic Tumor, Gastric Tumor, Esophageal Tumor, Lymphadenopathy, Duodenal Tumor
Interventions
Endoscopic ultrasound guided needle tissue acquisition.
Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
mistletoe extract, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cytomegalovirus
Interventions
CMV Immune globulin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
capecitabine, radiation therapy, bevacizumab, therapeutic conventional surgery, gemcitabine hydrochloride
Drug · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer in Inherited Bone Marrow Failure Syndromes

NCT00027274
Conditions
Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-927, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Cancer of Pancreas
Interventions
Walking Intervention
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional

Spectroscopy From Duodenum

NCT01753479
Conditions
Pancreatic Adenocarcinoma
Interventions
Spectroscopy device
Other
Lead sponsor
Olympus Corporation
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Conditions
Pancreatic Cancer
Interventions
Bevacizumab, Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
Conditions
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Biliary Disease, Pancreas Disease
Interventions
Laparoscopy assisted ERCP
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ipilimumab, Vaccine, FOLFIRINOX
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions
dd-cfDNA Blood Test
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin
Active, not recruiting Phase 4 Interventional

BEGIN Novel ImagiNG Biomarkers

NCT05517655
Conditions
Cystic Fibrosis
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 8 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia
Completed Not applicable Interventional Results available

Closed Loop Glucose Control in Patients With Type 2 Diabetes

NCT05386849
Conditions
Diabetes Mellitus, Type 2
Interventions
FUSION closed loop glucose control system
Device
Lead sponsor
Ideal Medical Technologies
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia